 VANCOUVER, British Columbia, Sept. 13, 2021 GLOBE NEWSWIRE -- InMed Pharmaceuticals Inc. InMed or the Company Nasdaq: INM, a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has entered into a definitive agreement Definitive Agreement to acquire BayMedica Inc. BayMedica, a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent the LOI announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. 